NO178186C - Forbindelser som kan koble metallioner til biologisk nyttige molekyler - Google Patents
Forbindelser som kan koble metallioner til biologisk nyttige molekylerInfo
- Publication number
- NO178186C NO178186C NO900838A NO900838A NO178186C NO 178186 C NO178186 C NO 178186C NO 900838 A NO900838 A NO 900838A NO 900838 A NO900838 A NO 900838A NO 178186 C NO178186 C NO 178186C
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- metal ions
- biologically useful
- useful molecules
- bifunctional
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229910021645 metal ion Inorganic materials 0.000 title abstract 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 4
- 230000001588 bifunctional effect Effects 0.000 abstract 3
- 229920002521 macromolecule Polymers 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- -1 alkyl hydrazone Chemical class 0.000 abstract 1
- 150000001491 aromatic compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Paints Or Removers (AREA)
- Manufacture Of Metal Powder And Suspensions Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31527089A | 1989-02-24 | 1989-02-24 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO900838D0 NO900838D0 (no) | 1990-02-22 |
| NO900838L NO900838L (no) | 1990-08-27 |
| NO178186B NO178186B (no) | 1995-10-30 |
| NO178186C true NO178186C (no) | 1996-02-07 |
Family
ID=23223639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO900838A NO178186C (no) | 1989-02-24 | 1990-02-22 | Forbindelser som kan koble metallioner til biologisk nyttige molekyler |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0384769B1 (sv) |
| JP (1) | JP3073997B2 (sv) |
| KR (1) | KR0142079B1 (sv) |
| AT (1) | ATE137219T1 (sv) |
| AU (1) | AU630668B2 (sv) |
| CA (1) | CA2010800C (sv) |
| DE (1) | DE69026637T2 (sv) |
| DK (1) | DK0384769T3 (sv) |
| ES (1) | ES2085890T3 (sv) |
| FI (1) | FI95907C (sv) |
| GR (1) | GR3019758T3 (sv) |
| HU (1) | HU207293B (sv) |
| IE (1) | IE74849B1 (sv) |
| IL (1) | IL93432A (sv) |
| NO (1) | NO178186C (sv) |
| NZ (2) | NZ239288A (sv) |
| PT (1) | PT93264B (sv) |
| ZA (1) | ZA901283B (sv) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792444A (en) * | 1989-05-09 | 1998-08-11 | The General Hospital Corporation | Labeled chemotactic peptides to image focal sites of infection or inflammation |
| US5589576A (en) * | 1989-08-29 | 1996-12-31 | Amersham International Plc | Cores for technetium radiopharmaceuticals |
| US6001979A (en) | 1989-08-29 | 1999-12-14 | Nycomed Amersham Plc | Cores for technetium radiopharmaceuticals |
| US5296599A (en) * | 1991-09-19 | 1994-03-22 | Millipore Corporation | Activated carbamates compounds |
| GB9209641D0 (en) * | 1992-05-02 | 1992-06-17 | Johnson Matthey Plc | Improvements in radiolabelling |
| GB9223168D0 (en) * | 1992-11-05 | 1992-12-16 | Johnson Matthey Plc | Improvements in molecule labelling |
| US5750088A (en) * | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
| WO1995003280A1 (en) * | 1993-07-19 | 1995-02-02 | Resolution Pharmaceuticals Inc. | Hydrazino-type radionuclide chelators having an n3s configuration |
| US5753206A (en) | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| US6686461B1 (en) | 2000-03-22 | 2004-02-03 | Solulink Bioscience, Inc. | Triphosphate oligonucleotide modification reagents and uses thereof |
| US7102024B1 (en) | 2000-08-01 | 2006-09-05 | Schwartz David A | Functional biopolymer modification reagents and uses thereof |
| CA2723664A1 (en) * | 2000-03-22 | 2001-09-27 | Solulink, Incorporated | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| PL1877099T3 (pl) | 2005-04-06 | 2013-02-28 | Genzyme Corp | Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą |
| WO2008089403A2 (en) | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharides comprising an aminooxy group and conjugates thereof |
| CN105879047A (zh) | 2008-12-16 | 2016-08-24 | 建新公司 | 寡糖-蛋白缀合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57181058A (en) * | 1981-04-30 | 1982-11-08 | Ikeda Mohandou:Kk | Compound labeled with 99m technetium, and its preparation |
| US4861869A (en) * | 1986-05-29 | 1989-08-29 | Mallinckrodt, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
| DE3728599A1 (de) * | 1986-12-10 | 1988-06-23 | Hoechst Ag | Verfahren zur herstellung einer mit technetium-99m-markierten organspezifischen substanz |
| US5066490A (en) * | 1988-06-01 | 1991-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Protein crosslinking reagents cleavable within acidified intracellular vesicles |
-
1990
- 1990-02-19 IL IL9343290A patent/IL93432A/en not_active IP Right Cessation
- 1990-02-20 ZA ZA901283A patent/ZA901283B/xx unknown
- 1990-02-20 KR KR1019900002035A patent/KR0142079B1/ko not_active IP Right Cessation
- 1990-02-22 AU AU50074/90A patent/AU630668B2/en not_active Expired
- 1990-02-22 NO NO900838A patent/NO178186C/no not_active IP Right Cessation
- 1990-02-23 ES ES90301949T patent/ES2085890T3/es not_active Expired - Lifetime
- 1990-02-23 CA CA002010800A patent/CA2010800C/en not_active Expired - Lifetime
- 1990-02-23 JP JP02041389A patent/JP3073997B2/ja not_active Expired - Fee Related
- 1990-02-23 NZ NZ239288A patent/NZ239288A/en unknown
- 1990-02-23 DK DK90301949.5T patent/DK0384769T3/da active
- 1990-02-23 PT PT93264A patent/PT93264B/pt active IP Right Grant
- 1990-02-23 DE DE69026637T patent/DE69026637T2/de not_active Expired - Lifetime
- 1990-02-23 EP EP90301949A patent/EP0384769B1/en not_active Expired - Lifetime
- 1990-02-23 AT AT90301949T patent/ATE137219T1/de not_active IP Right Cessation
- 1990-02-23 IE IE66690A patent/IE74849B1/en not_active IP Right Cessation
- 1990-02-23 NZ NZ232656A patent/NZ232656A/en unknown
- 1990-02-23 FI FI900948A patent/FI95907C/sv active IP Right Grant
- 1990-02-23 HU HU90970A patent/HU207293B/hu unknown
-
1996
- 1996-04-25 GR GR960400832T patent/GR3019758T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69026637D1 (de) | 1996-05-30 |
| CA2010800C (en) | 2001-01-16 |
| EP0384769A2 (en) | 1990-08-29 |
| HU207293B (en) | 1993-03-29 |
| IE74849B1 (en) | 1997-08-13 |
| EP0384769A3 (en) | 1991-11-27 |
| NO900838L (no) | 1990-08-27 |
| JP3073997B2 (ja) | 2000-08-07 |
| ZA901283B (en) | 1991-03-27 |
| DE69026637T2 (de) | 1996-09-26 |
| IL93432A (en) | 1994-02-27 |
| CA2010800A1 (en) | 1990-08-24 |
| IE900666L (en) | 1990-08-24 |
| AU5007490A (en) | 1990-09-13 |
| AU630668B2 (en) | 1992-11-05 |
| NO178186B (no) | 1995-10-30 |
| EP0384769B1 (en) | 1996-04-24 |
| FI95907B (sv) | 1995-12-29 |
| HUT53600A (en) | 1990-11-28 |
| PT93264A (pt) | 1990-08-31 |
| NZ232656A (en) | 1992-04-28 |
| KR900012910A (ko) | 1990-09-03 |
| GR3019758T3 (en) | 1996-07-31 |
| DK0384769T3 (da) | 1996-05-13 |
| HU900970D0 (en) | 1990-05-28 |
| PT93264B (pt) | 1996-01-31 |
| JPH0327356A (ja) | 1991-02-05 |
| ES2085890T3 (es) | 1996-06-16 |
| FI95907C (sv) | 1996-04-10 |
| ATE137219T1 (de) | 1996-05-15 |
| NZ239288A (en) | 1992-04-28 |
| NO900838D0 (no) | 1990-02-22 |
| KR0142079B1 (ko) | 1998-06-01 |
| FI900948A0 (sv) | 1990-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO178186C (no) | Forbindelser som kan koble metallioner til biologisk nyttige molekyler | |
| RU94036004A (ru) | Промежуточные соединения для получения ароматических аминоспиртовых производных | |
| ATE58297T1 (de) | Kupplungsmittel zum radiomarkieren von proteinen. | |
| DE69634912D1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
| HUT60484A (en) | Process for applying acid-splitted connecting molecules for the controlled release of biologically active compounds | |
| DK0468012T3 (da) | 17beta-substituerede 4-aza-5alfa-androstan-3-on-derivater og fremgangsmåde til fremstilling deraf | |
| ZA969489B (en) | Novel transfection agents and their pharmaceutical applications | |
| GR3026658T3 (en) | Hydrazino-type radionuclide chelators having an n 3?s configuration | |
| CY1108127T1 (el) | Μεθοδοι για την προστασια αλλογενους μοσχευματος παγκρεατικων νησιδιων με χρηση διαλυτων μοριων μεταλλακτων ctla4 | |
| NO952869D0 (no) | Aminosyrederivater, medikamenter inneholdende disse forbindelser og fremgangsmåter for fremstilling derav | |
| FI890311A0 (fi) | Kemiska foereningar. | |
| YU72594A (sh) | Vodeni rastvor inkluzionih kompleksa benzotiofen jedinjenja sa vodorastvornim ciklodekstrinima, njegove farmaceutske formulacije i postupci za dobijanje | |
| GR1000118B (el) | Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην. | |
| DE69434384D1 (de) | Metalkomplexbildner | |
| PH18031A (en) | Immunoglobulin conjugates,process for preparing them and pharmaceutical composition containing the same | |
| DE69425820D1 (de) | Verwendung von ferrioxamin-b zur behandlung septischen schocks | |
| CA2265444A1 (en) | Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods | |
| DK0570575T3 (da) | Bicykloazamakrocyklophosphonsyre, komplekser, konjugater, kontrastmidler og fremstilling heraf | |
| ES8306994A1 (es) | Procedimiento para la obtencion de diamidas de acido hidroxi-maloico sustituidas. | |
| Vogel | Preparation of immunoconjugates using antibody oligosaccharide moieties | |
| GEP19991535B (en) | Process for the Preparation of 7-Hydroxy Taxanes | |
| NO943847L (no) | Fremgangsmåte for fremstilling av makrocykliske chelateringsmidler og dannelse av chelater og konjugater derav | |
| RU94040719A (ru) | 2,3,4,5-тетрагидро-1h-3-бензазепины, фармацевтическая композиция, способ лечения и способ получения | |
| DK0426557T3 (da) | Fremgangsmåde til fremstilling af (1R,2R)-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamid-1-oxider, mellemprodukter anvendt ved denne fremgangsmåde og fremstilling af disse mellemprodukter | |
| NO953557L (no) | Antitumorpreparater og fremgangsmåte for deres fremstilling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |